Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. 1998

A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
Moscow Research Institute of Medical Ecology, Moscow, 113149, Russia.

The effect of antisense oligonucleotides complementary to the RNA component of human telomerase on telomerase activity in cell extracts of the melanoma cell line SK-Mel-28 has been studied. It has been shown that the antisense oligonucleotide complementary to the hTR component in the region of the template synthesis of telomeric repeats is the most efficient inhibitor of telomerase activity in comparison with other antisense oligonucleotides. Pronounced inhibition of telomerase activity was observed at the oligonucleotide (Tel P5) concentration in the reaction mixture of about 5 nM. Complete inhibition of the enzyme occurs at the oligonucleotide concentration in the sample of about 20 nM.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D019098 Telomerase An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES. Telomerase Catalytic Subunit,Telomerase Reverse Transcriptase,Telomerase Reverse Transcriptase Catalytic Subunit,Catalytic Subunit, Telomerase,Reverse Transcriptase, Telomerase,Subunit, Telomerase Catalytic,Transcriptase, Telomerase Reverse

Related Publications

A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
September 2006, Acta pharmacologica Sinica,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
September 2001, Shi yan sheng wu xue bao,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
August 2023, Nucleic acid therapeutics,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
April 2000, Antisense & nucleic acid drug development,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
February 1996, Acta virologica,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
May 2009, Journal of biomedical materials research. Part B, Applied biomaterials,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
September 2002, Current medicinal chemistry. Anti-cancer agents,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
July 2002, Cancer gene therapy,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
September 2008, Journal of bioscience and bioengineering,
A I Glukhov, and O V Zimnik, and S A Gordeev, and S E Severin
January 2014, BioMed research international,
Copied contents to your clipboard!